Truist Securities Reiterates Buy on Edgewise Therapeutics, Maintains $25 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Srikripa Devarakonda has reiterated a 'Buy' rating on Edgewise Therapeutics (NASDAQ:EWTX) and maintained a $25 price target.
June 28, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Edgewise Therapeutics (NASDAQ:EWTX) has been reiterated with a 'Buy' rating by Truist Securities, maintaining a $25 price target.
The reiteration of a 'Buy' rating by Truist Securities indicates a positive outlook for Edgewise Therapeutics. The maintained price target of $25 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor confidence and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100